United Therapeutics focuses on innovative technologies aimed at addressing unmet medical needs, particularly in the field of pulmonary arterial hypertension (PAH) and organ transplantation. The company has developed a range of therapeutic products that utilize advanced drug delivery systems, including inhalation therapies and implantable devices. These technologies are designed to enhance the efficacy and convenience of treatment for patients, allowing for more targeted and sustained delivery of medications.

In addition to its drug delivery innovations, United Therapeutics is also engaged in cutting-edge research in regenerative medicine and organ manufacturing. The company is exploring the use of 3D printing and tissue engineering to create viable organs for transplantation, which could significantly alleviate the shortage of donor organs. This commitment to leveraging advanced scientific techniques underscores United Therapeutics' mission to improve patient outcomes and expand treatment options in critical areas of healthcare.

United States

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! Our employees can be found collaborating across the United States, Europe and Asia.  As a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases.

Cancer

Cardiovascular Diseases

Kidney Diseases

Liver Diseases

Lung Diseases

United Therapeutics

Pulmonary hypertension

Treprostinil is a prostacyclin analogue. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.

Tyvaso (inhaled treprostinil)

Remunity™ (treprostinil)

Tyvaso DPI™, previously referred to as Treprostinil Technosphere®, is an investigational drug-device combination therapy comprised of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler. If approved, Tyvaso DPI is expected to provide a more convenient method of administration compared with traditional nebulized Tyvaso® therapy. United Therapeutics is developing Tyvaso DPI under a collaboration and license agreement with MannKind Corporation. Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat® inhalation device technology used in MannKind's Afrezza® (insulin human) Inhalation Powder product, which was approved by the FDA in 2014.

Tyvaso DPI™ (inhaled treprostinil)

Ralinepag (IP receptor agonist)

Idiopathic pulmonary fibrosis

Pulmonary fibrosis

Progressive pulmonary fibrosis

TYVASO promotes direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation

United Therapeutics

Company Details